Posted by Michael Wonder on 08 Oct 2023
A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier
6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 and the share that would surpass the NICE “size of benefit” decision weight thresholds.
The FDA approved 483 new therapies between 2011 and 2021 and of these 252 had a published cost effectiveness analysis meeting our inclusion criteria. The average incremental health benefits produced by these treatments were 1.04 QALYs (SD = 2.00) relative to standard of care, with wide variation by therapeutic area.
